Company Overview
Snapshot
Founded in February 2007, Molecular Detection operates with 11–50 employees. The company is currently in the Pre-Funding stage, focusing on developing its core technology.
Business overview
Molecular Detection is a Health Tech & Life Sciences company specializing in medical technologies within the Diagnostics Devices sector. The company is developing SEPSIS-xxpress, a hospital-based instrument designed for rapid sepsis diagnosis and pathogen profiling. This system aims to provide doctors with specific pathogen and antibiotic-resistance information in the critical early hours of infection, serving hospitals in markets such as China and the United States.
Log in to access full profile ›Company Intelligence Q&A
- What is Molecular Detection's primary product?
- Molecular Detection's primary product is SEPSIS-xxpress, an instrument platform with embedded touchscreen computer and test kits designed for rapid sepsis diagnosis and pathogen profiling.
- What problem does SEPSIS-xxpress address?
- SEPSIS-xxpress addresses the need for rapid sepsis diagnosis and pathogen profiling, providing doctors with crucial information on specific pathogens and antibiotic-resistance profiles to treat infections in their early stages.
- What is the operational status of Molecular Detection?
- Molecular Detection is currently in a Non Active status as of October 2016.
- In which markets does Molecular Detection operate?
- Molecular Detection operates in geomarkets including China and the United States.
- What is the current product stage of SEPSIS-xxpress?
- The SEPSIS-xxpress product is currently in the R&D stage, with the system comprising an instrument platform with embedded touchscreen computer and test kits with single-use, disposable cartridges pre-loaded with all needed reagents.